Honasa Consumer, the parent company behind the Mamaearth brand, announced on Tuesday that it has called off the proposed ₹135 crore purchase of a 58 percent stake in nutraceutical startup Fluence Pharma.
Deal Called Off After Closing Conditions Unmet
The company filed a notice with the stock exchange stating the acquisition was terminated because certain closing conditions outlined in the share purchase agreement were not satisfied. The filing did not identify the specific conditions that were missed. Honasa said the decision was taken in accordance with the agreement.
The deal fell apart, leaving a gap in the schedule.
Honasa’s board had approved the transaction in June, planning to buy the 58 percent stake from Fluence Pharma’s existing shareholders for ₹135 crore. The secondary deal was slated for completion within eight weeks, contingent on the fulfillment of predefined conditions.
Closing conditions in such agreements often cover regulatory approvals, financing arrangements and the outcome of due‑diligence reviews. Failure to meet any of these milestones can give the buyer the right to walk away, as Honasa exercised.
The proposal also included acquiring the remaining 42 percent through two secondary tranches over the next five to seven years. Those future purchases were meant to give Honasa full control of Fluence Pharma’s operations.
Even though the transaction did not close, Honasa reiterated its dedication to building a nutraceuticals platform. The company emphasized that it will keep scouting both internal development routes and external partnerships to strengthen its presence in the “inside‑out” health segment, where consumers are looking for solutions that address skin and hair concerns from within.
Related: Traditional menswear sees revival
Fluence Pharma’s core offering revolves around a patented cyclical nutrition therapy that is delivered exclusively via a network of thousands of dermatologists and trichologists. By leveraging that clinical channel, the startup has been able to position its skin and hair supplements as specialist‑recommended products, differentiating them from typical over‑the‑counter alternatives.
Honasa envisioned that combining this clinical distribution model with its own consumer‑brand expertise, extensive offline reach, and digital marketing engine could create a powerful cross‑sell opportunity. The plan was to let its well‑known brands benefit from the credibility of medical endorsement while extending the reach of Fluence’s formulations to a broader retail audience.
The creation of a wholly owned subsidiary, Honasa Health, was approved alongside the acquisition. This new entity is tasked with overseeing the entire B2C value chain for nutraceuticals, from product development and regulatory compliance to logistics, e‑commerce, and retail activation. By housing the operation in a dedicated unit, Honasa aims to maintain focus on the specific demands of health‑oriented consumers while preserving the agility needed for rapid product launches.
Within the broader five‑year “Honasa 3.0” roadmap, nutraceuticals are positioned as a central growth pillar. The strategy calls for expanding the portfolio beyond the flagship skin‑care line, diversifying revenue streams, and reducing reliance on any single brand. The plan also outlines an aggressive push to broaden the offline footprint, targeting a substantial increase in the number of points of sale across the country.
Honasa’s track record of strategic acquisitions—spanning skincare, haircare, men’s personal care, and a recent minority stake in an oral‑care brand—demonstrates its willingness to enter adjacent categories through targeted deals. Those past moves have provided the company with product expertise, distribution synergies, and brand equity that can be repurposed for future nutraceutical initiatives.
Financially, the company has shown strong momentum, with quarterly earnings and revenue reaching new highs. This performance underpins its capacity to fund ambitious expansion plans, whether through organic product development or further acquisitions that align with its long‑term vision.
